$CORT — what investors on X are saying · SpikePanel
$CORT — investor discussion on X
About the company
Corcept sells Korlym, a once-daily pill for Cushing's syndrome, a hormonal disorder causing high blood sugar. Think of it as a targeted key for a rare lock.
Revenue comes almost entirely from Korlym, with gross margins around 98%. Net margins swung from 22% in 2023 to 13% in 2025, reflecting higher R&D spending.
Korlym is the only approved treatment for its specific Cushing's population, and Corcept holds patents. However, newer drugs from companies like Novartis and Recordati could challenge it, so the moat is eroding.
